Sanofi to buy Bioverativ for $11.6bn

Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Europe

Sanofi in talks to sell generics unit for €1.9bn

19 April 2018 France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.

Americas

Sanofi unit takes CSL to court over haemophilia therapy

5 March 2020 Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix.

More on this story

Americas

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Europe

Sanofi in talks to sell generics unit for €1.9bn

19 April 2018 France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.

Americas

Sanofi unit takes CSL to court over haemophilia therapy

5 March 2020 Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix.

More on this story

Americas

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Europe

Sanofi in talks to sell generics unit for €1.9bn

19 April 2018 France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.

Americas

Sanofi unit takes CSL to court over haemophilia therapy

5 March 2020 Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix.